|
| |
ThromboGenics NVThromboGenics is a biopharmaceutical company focused on the development of therapeutics for conditions related to the vascular system. The Company has used its in house expertise to build a significant pipeline of promising drug candidates, a number of which are in clinical trials. The Company is focused on developing new medicines to treat visual disorders, cardiovascular diseases, and cancer, conditions which result from abnormalities to the vascular system. ThromboGenics’ lead product is microplasmin, a stable proteolytic enzyme which is in Phase II trials for eye disease and thrombotic disease.
The Company plans to show proof-of-concept for its products by taking them through to completion of Phase II clinical trials. To leverage its expertise in the development and regulatory approval process, ThromboGenics selectively forms development and marketing collaborations with experienced partners in the pharmaceutical industry. Such collaborations can lead to ThromboGenics generating revenues via milestone payments, as well as royalties on commercial sales.
ThromboGenics was founded by Professor Désiré Collen and the Katholieke Universiteit Leuven (KULeuven) (Belgium) in 1991. Since then it has developed a further important research relationship with the Flanders Interuniversity Institute for Biotechnology (VIB) (Belgium).
| Contact Details: |
| Campus GasthuisbergHerestraat 49 |
| Leuven |
| |
| B-3000 |
| Belgium |
| Tel: | 32 (0)16 346194 |
| Fax: | 32 (0)16 345990 |
| Email: | |
| WWW: | www.thrombogenics.com/
|
| |
Press Releases on ThromboGenics NV:
|
 |
| ThromboGenics and BioInvent Complete Phase I Patient Trial of Anti-PlGF Cancer Therapeutic TB-403 in Patients With Advanced Solid Tumours |
16th November, 2009 |
|
LEUVEN, Belgium and LUND, Sweden, November 16 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR) and BioInvent
International AB (OMXS: BINV) today announced positive results from a Phase I
|
| ThromboGenics NV - Q3 2009 Business Update |
4th November, 2009 |
|
LEUVEN, Belgium, November 4 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical
company focused on innovative medicines for eye disease, vascular disease and
cancer, is
|
| ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME) |
5th October, 2009 |
|
LEUVEN, Belgium, October 5 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical
company focused on the discovery and development of innovative medicines for
eye disease,
|
| ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009 |
11th September, 2009 |
|
LEUVEN, Belgium, September 11 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company
focused on the discovery and development of innovative treatments for
eye disease,
|
| ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule |
25th June, 2009 |
|
LEUVEN, Belgium, June 25 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology
company focused on the discovery and development of innovative treatments for
eye disease, vascular
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 232 times since April 2007, the link to the organisation's website has been followed 36 times Search for more companies in Leuven Search for more companies in This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for ThromboGenics NV |
